Saturday links: limited time
Tadas Viskanta
Abnormal Returns
2 weeks ago
3 MIN READ
Autos
- American reluctance aside, EVs continue to grow worldwide. (axios.com)
- GM ($GM) is promising cheaper, longer-lasting batteries, i.e. lithium-manganese-rich. (techcrunch.com)
- Ride-share drivers are having an increasingly hard time making money at LAX. (nytimes.com)
Transport
- By any measure, congestion pricing is a boon to midtown. (nytimes.com)
- Need an icebreaking ship? Head to Finland. (wsj.com)
Energy
- Battery maker CATL is set to go public. (ft.com)
- How wind farms can steal from each other. (bbc.com)
- Opposition to renewables comes down to spite. (paulkrugman.substack.com)
- Why go after a popular program like Energy Star? (newyorker.com)
Environment
- The National Weather Service is struggling to keep up. (cnn.com)
- The EPA is shuttering the Office of Research and Development. (wired.com)
- The NOAA has killed another database. (cnn.com)
FAA
- We’ve been underinvesting in the FAA for decades. (theatlantic.com)
- The problems at Newark ATC are not new or unique. (nytimes.com)
Travel
- United ($UAL) and American ($AAL) are battling over O’Hare. (wsj.com)
- Contrary to hopes, travel hasn’t brought the world together. (ft.com)
- Will tourism to the U.S. rebound? (apolloacademy.com)
Space
Behavior
- Five insights from “What We Value: The Neuroscience of Choice and Change” by Emily Falk. (nextbigideaclub.com)
- How our notions of happiness have shifted. (nytimes.com)
- We humans love pyramids. (daily.jstor.org)
- Everyone is suffering. (freddiedeboer.substack.com)
Vaccines
- Moderna’s ($MRNA) combo Covid-flu vaccine works better than alternatives. Don’t expect it to be approved any time soon. (nbcnews.com)
- What diseases will ‘inverse vaccines’ treat? (theguardian.com)
Good news
- A different drug for treating diabetes, SGLT2 inhibitors, may help treat other diseases. (worksinprogress.news)
- This baby was healed with the worlds’ first personalized gene-editing treatment. (nytimes.com)
- Technology is making hearing aids better. (vox.com)
Public health
- The trends driving America’s poor health. (wsj.com)
- Other countries have an opening to poach American scientists. (nytimes.com)
- UnitedHealth ($UNH) is under investigation for Medicare fraud. (wsj.com)
- Fluoride truthers now run the FDA. (npr.org)
Nicotine
- The CDC is cutting funding for anti-smoking and vaping programs. (nytimes.com)
- Quitting Zyn ain’t easy. (nytimes.com)
Drugs
- Opioid overdose death rates have fallen to 2019 levels. (axios.com)
- A quarter of American children have a parent with a substance abuse problem. (npr.org)
- How cocaine flows freely around the world. (wsj.com)
Food
- At hot restaurants, OpenTable) is paying to push Resy aside. (nytimes.com)
- How Chomps’ meat sticks became a thing. (bloomberg.com)
Pop
- This is Gregg Popovich’s real legacy. (theatlantic.com)
- Gregg Popovich’s success came with the help of foreign players. (bloomberg.com)
Children
- What it means to be a ‘good enough’ parent. (joylere.substack.com)
- Everyone kid has an ‘island of competence.’ How to build on it. (theatlantic.com)
College
- Ann Garcia, “If someone tells you that you’ll get more financial aid if you don’t save for college, please ignore Every. Single. Thing. they say on the topic of college planning.” (thecollegefinanciallady.com)
- How Grinnell College’s endowment got caught up in the war on colleges. (bloomberg.com)
Earlier on Abnormal Returns
- What you missed in our Friday linkfest. (abnormalreturns.com)
- Podcast links: privacy protections (abnormalreturns.com)
- Don’t miss a thing! Sign up for our daily e-mail newsletter. (abnormalreturns.com)
Mixed media
Terms and Conditions
This content, which contains security-related opinions and/or information, is provided for informational purposes only and should not be relied upon in any manner as professional advice, or an endorsement of any practices, products or services. There can be no guarantees or assurances that the views expressed here will be applicable for any particular facts or circumstances, and should not be relied upon in any manner. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment.
The commentary in this “post” (including any related blog, podcasts, videos, and social media) reflects the personal opinions, viewpoints, and analyses of the Ritholtz Wealth Management employees providing such comments, and should not be regarded the views of Ritholtz Wealth Management LLC. or its respective affiliates or as a description of advisory services provided by Ritholtz Wealth Management or performance returns of any Ritholtz Wealth Management Investments client.
References to any securities or digital assets, or performance data, are for illustrative purposes only and do not constitute an investment recommendation or offer to provide investment advisory services. Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others.
Please see disclosures here.
